Welcome to CDC stacks | Updated Recommendations for use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months - 7439 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Updated Recommendations for use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months
  • Published Date:
    June 26, 2009
  • Status:
    retired
  • Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(24):673-4.
  • Language:
    English
Filetype[HTML]
View this content


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Corporate Authors:
    United States. Advisory Committee on Immunization Practices. ; American Academy of Family Physicians. ; American Academy of Pediatrics.
  • Keywords:
  • Pubmed ID:
    19553904
  • Description:
    On December 13, 2007, certain lots of Haemophilus influenzae type b (Hib) vaccine marketed as PedvaxHIB (monovalent Hib vaccine) and Comvax (Hib-HepB vaccine), and manufactured by Merck & Co., Inc., were recalled voluntarily, and the company temporarily suspended production of these vaccines. To conserve the limited supply of Hib-containing vaccines, CDC, in consultation with the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), and the American Academy of Pediatrics (AAP), on December 18, 2007, recommended that vaccination providers temporarily defer the routine Hib vaccine booster dose administered to most healthy children at age 12-15 months

  • Document Type:
    Journal Issue
  • Collection(s):
    Guidelines and Recommendations
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. MMWR. Morbidity and mortality weekly report, Vol. 58, no. 24, June 26, 2009
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    June 26, 2009
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 48, no. 24
    Description:
    National HIV Testing Day--June 27, 2009 -- Late HIV Testing--34 States, 1996-2005 -- HIV Testing Among High School Students--United States, 2007 -- Progress Toward the 2012 Measles Elimination Goal--Western Pacific Region, 1990-2008 -- Updated Recomm...
    File Type:
    Filetype[PDF - 1.28 MB]
  2. DBD bulletin ; issue 03, summer 2009
    Corporate Author:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases.
    Published:
    summer 2009
    Series:
    DBD bulletin ; issue 3
    Description:
    DBD & The Recovery Act of 2009 -- DBD Answers the Call: H1N1 Response -- Pertussis Clinical Validation Study -- PPV23 During an Influenza Pandemic.
    File Type:
    Filetype[PDF - 240.95 KB]
  3. Haemophilus influenzae Type b Disease and Vaccine Booster Dose Deferral, United States, 1998–2009
    Personal Author:
    Briere, Elizabeth C.; Jackson, Michael; Shah, Shetul G.; Cohn, Amanda C.; Anderson, Raydel D.; MacNeil, Jessica R.; Coronado, Fatima M.; Mayer, Leonard W.; Clark, Thomas A.; Messonnier, Nancy E.;
    Published:
    Aug 06 2012
    Source:
    Pediatrics. 130(3):414-420.
    Description:
    BACKGROUND : Since the introduction of effective vaccines, the incidence of invasive Haemophilus influenzae type b (Hib) disease among children <5 years of age has decreased by 99% in the United States. In response to a limited vaccine supply that...
    File Type:
    Filetype[PDF - 319.97 KB]
  4. MMWR. Morbidity and mortality weekly report, Vol. 59, no. 33, August 27, 2010
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    August 27, 2010
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 59, no. 33
    Description:
    Estimates of Deaths Associated with Seasonal Influenza--United States, 1976-2007 -- Tobacco Use Among Middle and High School Students--United States, 2000-2009 -- Changes in Measurement of Haemophilus influenzae serotype b (Hib) Vaccination Coverage-...
    File Type:
    Filetype[PDF - 1.93 MB]
  5. Licensure of a Haemophilus influenzae type b (Hib) Vaccine (Hiberix) and updated recommendations for use of Hib vaccine
    Published:
    September 18, 2009
    Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(36):1008-9.
    Description:
    On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) conjugate vaccine composed of H. influenzae type b capsular polysaccharide (polyribos...
    Status:
    current
    File Type:
    Filetype[HTML]